Invention Grant
US08703784B2 Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin
有权
雷帕霉素[1,5-a]吡啶并[3,2-e]嘧啶-6-酮抑制剂雷帕霉素哺乳动物靶标
![Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin](/docs/US/2014-04-22/US08703784B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin
- Patent Title (中): 雷帕霉素[1,5-a]吡啶并[3,2-e]嘧啶-6-酮抑制剂雷帕霉素哺乳动物靶标
-
Application No.: US13818153Application Date: 2011-08-22
-
Publication No.: US08703784B2Publication Date: 2014-04-22
- Inventor: Zhaoyang Meng , Panduranga Adulla P. Reddy , M. Arshad Siddiqui , Amit K. Mandal , Duan Liu , Lianyun Zhao , Andrew McRiner
- Applicant: Zhaoyang Meng , Panduranga Adulla P. Reddy , M. Arshad Siddiqui , Amit K. Mandal , Duan Liu , Lianyun Zhao , Andrew McRiner
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Li Su; Laura M. Ginkel
- International Application: PCT/US2011/048539 WO 20110822
- International Announcement: WO2012/027234 WO 20120301
- Main IPC: A61K31/505
- IPC: A61K31/505
![Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin](/abs-image/US/2014/04/22/US08703784B2/abs.jpg.150x150.jpg)
Abstract:
This invention relates to novel fused tricyclic compounds under Formula I that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.
Public/Granted literature
- US20130150353A1 Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin Public/Granted day:2013-06-13
Information query
